Bracco Imaging S.p.A., a global leading company in the diagnostic imaging business, announced today that through its U.S. subsidiary Bracco Diagnostic Inc., has signed an agreement with PHS Technologies Group, LLC, a division of PACSHealth™, LLC to promote, market and distribute DoseMonitor ® globally.

DoseMonitor is an automated software solution that monitors and reports the radiation dose received during diagnostic imaging procedures. This important data provides healthcare organizations the information needed to enhance patient safety, ensure imaging exam consistency, maintain regulatory compliance, and manage radiation dose at an enterprise level from a single application.

“We are pleased to partner with Bracco Imaging. Our combined medical imaging expertise will deliver an innovative, customer focused solution set in preparation for the many changes in healthcare delivery,” said Mike Battin, COO of PACSHealth.

“Radiation dose monitoring is an important customer need and an industry priority. The addition of DoseMonitor to our solutions portfolio fortifies our ability to meet our customers’ comprehensive imaging needs,” said Fulvio Renoldi Bracco, Head of Global Business Unit Imaging at Bracco.

About Bracco Imaging Bracco Imaging S.p.A., part of the Bracco Group, is one of the world’s leading companies in the diagnostic imaging business. Headquartered in Milan, Italy, Bracco Imaging develops, manufactures and markets diagnostic imaging agents and solutions that meet medical needs.

Bracco Imaging offers a product and solution portfolio for all key diagnostic imaging modalities: X-Ray Imaging (including Computed Tomography-CT, Interventional Radiology, and Cardiac Catheterization), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS), Nuclear Medicine through radioactive tracers, and Gastrointestinal Endoscopy. The diagnostic imaging offer is completed by several medical devices and advanced administration systems for contrast imaging products in the fields of radiology.

The Company operates in over 90 markets worldwide, either directly or indirectly, through subsidiaries, joint ventures, licenses and distribution partnership agreements. With an on-going research covering all key modalities, Bracco Imaging has a strong presence in key geographies: North America; Europe and Japan operating through the Joint Venture Bracco-Eisai Co., Ltd. The Company also operates in Brazil, South Korea, and China through the Joint Venture Bracco Sine Pharmaceutical Corp. Ltd.

Operational investments have been made in order to achieve top quality and compliance with a sustainable eco-friendly production. Manufacturing activities are located in Italy, Switzerland, Japan, China and Germany.

Bracco Imaging is an innovative Research and Development (R&D) player with an efficient process oriented approach and a track record of innovation in the diagnostic imaging industry. R&D activities are managed in the three Research Centres located in Italy, Switzerland and the USA.